Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05804149Phase 2Completed
Phase 2, randomised, open-label trial (2 arms), sponsored by Cairo University. Primary endpoints: Thyroid Stimulating Hormone at 4 months, Free Tetraiodothyronine at 4 months and 4 more. Started Aug 2020; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05804149.